logo

For the Inventor, By the Inventor

Oxford, United Kingdom

Prosidion Limited

USPTO Granted Patents = 16

% Expired Patents = 81.3



Forward Citations = 101

Loading Chart...
Loading Chart...

38 inventors (with patents filed for the assignee):

goldMedal Martin James Procter (7 out of 24 patents)

silverMedal Matthew Colin Thor Fyfe (7 out of 17 patents)

bronzeMedal Karen Lesley Schofield (6 out of 12 patents)

4.  Chrystelle Marie Rasamison (5 out of 6 patents)

5.  Stuart Edward Bradley (5 out of 15 patents)

6.  Hans-Ulrich Demuth (4 out of 66 patents)

7.  Lisa Sarah Gardner (4 out of 4 patents)

8.  Gerard Hugh Thomas (4 out of 6 patents)

9.  Vilasben Kanji Shah (4 out of 10 patents)

10.  Thomas Martin Krulle (3 out of 8 patents)

11.  Torsten Hoffmann (3 out of 29 patents)

12.  Kosuke Yasuda (3 out of 16 patents)

13.  Maseo Nawano (3 out of 3 patents)

14.  Jason Bloxham (2 out of 5 patents)

15.  Colin Peter Sambrook-Smith (2 out of 2 patents)


16 patents:

1. 8664397 - Pyrrolopyridine-2-carboxylic acid amide derivative useful as inhibitor of glycogen phosphorylase (2014-03-04),
2. 8278442 - Bicyclic aryl and heteroaryl compounds for the treatment of metabolic disorders (2012-10-02),
3. 8207147 - Heterocyclic derivatives as GPCR receptor agonists (2012-06-26),
4. 8193359 - G-protein coupled receptor agonists (2012-06-05),
5. 8173807 - Pyridine, pyrimidine and pyrazine derivatives as GPCR agonists (2012-05-08),
6. 8158622 - Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase (2012-04-17),
7. 8063247 - Bicyclic aryl and heteroaryl receptor modulators (2011-11-22),
8. 7745491 - Substituted phenylacetamides and their use as glucokinase activators (2010-06-29),
9. 7582632 - Tri(cyclo) substituted amide compounds (2009-09-01),
10. 7262196 - Tri(cyclo) substituted amide glucokinase activator compounds (2007-08-28),
11. 7214681 - Tri(cyclo) substituted amide compounds (2007-05-08),
12. 7166579 - Prodrugs of DP IV-inhibitors (2007-01-23),
13. 7083933 - Methods for identification of modulators of OSGPR116 activity (2006-08-01),
14. 7060719 - Glutaminyl based DPIV inhibitors (2006-06-13),
15. 7053055 - Compounds of unstable DP IV-inhibitors (2006-05-30),
Company Overview
Prosidion Limited, based in Oxford, specializes in the development of innovative therapeutics, particularly in the field of diabetes and metabolic diseases. The company focuses on advancing drug discovery through its proprietary technologies, aiming to address significant unmet medical needs. With a strong emphasis on research and development, Prosidion collaborates with various partners to enhance its therapeutic offerings and contribute to the evolving landscape of healthcare solutions.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

16 Patents

#17 in Oxford

#1,118 in United Kingdom

#37,868 in the World

Oxford, GB
Oxford, United Kingdom

Prosidion Limited

Forward Citations = 101

38 inventors:

goldMedal Martin James Procter (7 out of 24 patents)

silverMedal Matthew Colin Thor Fyfe (7 out of 17 patents)

bronzeMedal Karen Lesley Schofield (6 out of 12 patents)

4.  Chrystelle Marie Rasamison (5 out of 6 patents)

5.  Stuart Edward Bradley (5 out of 15 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Prosidion Limited. Retrieved from https://idiyas.com/company/prosidion

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…